In this article, we will take a look at Billionaire Stan Druckenmiller’s 10 Stock Picks with Huge Upside Potential.
Stanley Druckenmiller, an American billionaire investor, is the founder of Duquesne Capital. Having amassed his fortune via a prosperous thirty-year career managing hedge funds, today he oversees investments through his family firm. His stint as head trader at the Quantum Fund, where he collaborated with renowned financier George Soros, helped him define his unique approach to investing.
Renowned for using what he calls a disciplined and well-timed trading rhythm, Druckenmiller uses a top-down approach that combines long and short bets in order to profit from market trends. The Financial Times reports that in his years of managing his hedge fund and the family office, the seasoned investor has never had a down year.
With two of his protégés now well-established in Donald Trump’s inner circle, the 71-year-old billionaire’s influence is also growing beyond the realm of high finance. Druckenmiller’s opinions on economic policy have instantly gained greater clout thanks to Kevin Warsh, a strong candidate to become the next chair of the Federal Reserve, and Scott Bessent, the US president’s Treasury secretary.
Despite this, the billionaire has made it clear that he dislikes President Donald Trump’s sweeping “reciprocal tariffs” and the subsequent market selloff, stating that he doesn’t think taxes on imports should be more than 10%.
Stanley Druckenmiller of Duquesne Capital
Our Methodology
For this article, we examined Duquesne Capital’s Q1 2025 13F filings to list down Stanley Druckenmiller’s stock picks with the highest upside potential. We ranked the companies in ascending order of their upside potential. These equities are also popular among elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10. BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Duquesne Capital’s Stake Value: $15.1 million
Analyst Upside as of June 15: 44.20%
Number of Hedge Fund Holders: 59
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. With a price target of $63, Piper Sandler analysts reaffirmed their Overweight rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on June 6. The analysts drew attention to the upcoming Phase 3 topline readout of the CALIBRATE study for BridgeBio Pharma’s calcilytic medication encaleret. The study’s findings are expected to be made public in the second half of 2025.
According to the analysts, the CALIBRATE study, which includes 67 individuals with autosomal dominant hypocalcemia type 1 (ADH1), is expected to have a favorable outcome given the positive efficacy findings from the Phase 2b study of encaleret in patients with ADH1. With a 40% discount, they calculated that risk-adjusted peak sales for ADH1 in the American and EU markets would amount to $389 million. This figure is equivalent to about 9% of BridgeBio Pharma’s overall product revenue.
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a biopharmaceutical company that was founded to discover, develop, evaluate, and market cutting-edge medication to cure genetic illnesses.
9. Ascendis Pharma A/S (NASDAQ:ASND)
Duquesne Capital’s Stake Value: $24.7 million
Analyst Upside as of June 15: 29.20%
Number of Hedge Fund Holders: 52
Ascendis Pharma A/S (NASDAQ:ASND) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. Oppenheimer maintained its Outperform rating on Ascendis Pharma A/S (NASDAQ:ASND) while increasing its price target from $215 to $224 on June 13.
The change comes after a commissioned survey of 20 endocrinologists in the United States who treat hypoparathyroidism showed a high initial demand for the company’s drug, Yorvipath. According to doctors, 20–30% of their hypoparathyroid patients are expected to be taking the medication within a year.
According to the poll, 90% of physicians would recommend Yorvipath to maintain kidney function before renal impairment develops. This affinity is consistent with the prevalence of renal impairment among patients with hypoparathyroidism.
The primary barriers to adoption, according to the majority of physicians, are access and reimbursement; however, Oppenheimer indicated that these worries “may be more anticipation than reality.” Yorvipath’s first full quarter in the United States was described by the firm as “just the beginning of a launch that will outpace expectations.”
Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops and distributes novel treatments for unmet medical needs, especially in the fields of oncology and endocrinology.
8. United Airlines Holdings, Inc. (NASDAQ:UAL)
Duquesne Capital’s Stake Value: $25.45 million
Analyst Upside as of June 15: 41.41%
Number of Hedge Fund Holders: 67
United Airlines Holdings, Inc. (NASDAQ:UAL) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. Jefferies maintained its buy rating on United Airlines Holdings, Inc. (NASDAQ:UAL) and increased its price target from $80 to $100 on June 12. According to the research firm, United’s second-quarter earnings per share of $3.90 are in line with the company’s prior guidance range of $3.25–$4.25. That said, the airline was unable to meet the upper end of that range due to operational difficulties and Newark Airport booking issues.
Due to ongoing challenges at Newark Airport, which accounts for 20% of United’s available seat miles, and a policy of trading yields for load factors during peak summer travel, Jefferies expects third-quarter earnings per share of $2.55, which is about 10% less than the consensus estimates of $2.84.
For United’s full-year results, the firm stressed that close-in bookings for the third quarter along with performance in the fourth quarter will be critical, especially to ascertain whether the currently steady demand accelerates. To that end, Jefferies projects United Airlines Holdings, Inc. (NASDAQ:UAL)’s 2025 EPS to be at $10, which is lower than the company’s initial target range of $11.50-$13.50.
United Airlines Holdings, Inc. (NASDAQ:UAL) is a well-known airline company whose mainline and regional fleets transport both passengers and freight across the globe.
7. Daktronics, Inc. (NASDAQ:DAKT)
Duquesne Capital’s Stake Value: $37.36 million
Analyst Upside as of June 15: 89.78%
Number of Hedge Fund Holders: 14
Daktronics, Inc. (NASDAQ:DAKT) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. Daktronics, Inc. (NASDAQ:DAKT) announced on June 13 that it was engaging into a fourth amendment to its credit arrangement with JPMorgan Chase, which would take effect on June 6. Through this change, the company can obtain Letters of Credit that, under specific circumstances, may mature after the current maturity date of May 11, 2026.
The company’s financial situation, which reflects its careful management style, is shown in its $42.52 million total debt. Additionally, after receiving shareholder approval, Daktronics, Inc. (NASDAQ:DAKT) has successfully reincorporated from South Dakota to Delaware. This move brings the company into compliance with Delaware’s General Corporation Law as of April 17.
Daktronics, Inc. (NASDAQ:DAKT) is an American company that creates, produces, markets, and maintains scoreboards, digital billboards, dynamic message signs, video displays, sound systems, and associated products. These are used in a variety of contexts, including live events, commercial advertising, transit networks, and sports arenas.
6. Eli Lilly and Company (NYSE:LLY)
Duquesne Capital’s Stake Value: $78.3 million
Analyst Upside as of June 15: 23.55%
Number of Hedge Fund Holders: 119
Eli Lilly & Company (NYSE:LLY) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. Bernstein SocGen Group reaffirmed its Outperform rating and $1,100 price target for Eli Lilly & Company (NYSE:LLY) on June 13 ahead of the 85th Annual Meeting of the American Diabetes Association.
The firm outlined a number of crucial data presentations that Eli Lilly & Company (NYSE:LLY) is expected to provide at the next meeting. One of these is the full description of the ACHIEVE-1 study, which is the first phase 3 trial from the late-stage clinical program of orforglipron. Bernstein is especially keen to acquire more information on the negative event profile and discontinuation rates, even if topline data is already available.
Additionally, Eli Lilly & Company (NYSE:LLY) will provide information about its muscle-wasting medication, bimagrumab. When paired with tirzepatide, this will be the first clinical data reported for an anti-muscle wasting agent used in conjunction with a GLP-1 receptor agonist, possibly hinting at future use cases.
Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world’s largest pharmaceutical companies.
5. DocuSign, Inc. (NASDAQ:DOCU)
Duquesne Capital’s Stake Value: $87.47 million
Analyst Upside as of June 15: 21.21%
Number of Hedge Fund Holders:
DocuSign Inc. (NASDAQ:DOCU) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. RBC Capital analysts maintained their price target at $90 for DocuSign Inc. (NASDAQ:DOCU) alongside a Sector Perform rating on June 6. The update followed the company’s recent quarterly report, which revealed mixed results.
DocuSign Inc. (NASDAQ:DOCU)reported weaker-than-expected billings growth, which contributed to the company’s price falling by 17% during after-hours trading. The company reported that despite its net revenue retention (NRR) staying steady at 101%, its billings growth was just 4% greater year-over-year, falling short of both guidance and the consensus.
The company also updated its fiscal year 2026 billings projection, reducing it by $15 million below the midpoint consensus. In addition, the second quarter billings guidance fell short of expectations. That said, improved gross retention along with increased IAM upsells might lead to increases in dollar net retention over the year, according to management.
DocuSign Inc. (NASDAQ:DOCU) is a global provider of electronic signature solutions. It delivers document generation, contract lifecycle management (CLM), and an AI-powered Intelligent Agreement Management (IAM) platform.
4. MercadoLibre, Inc. (NASDAQ:MELI)
Duquesne Capital’s Stake Value: $104.8 million
Analyst Upside as of June 15: 21.12%
Number of Hedge Fund Holders: 108
MercadoLibre, Inc. (NASDAQ:MELI) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. Analysts at BofA Securities reiterated their Buy rating on MercadoLibre, Inc. (NASDAQ:MELI) and maintained their price target of $3,000 on June 6. The analysts emphasized the possible effects of changing the company’s shipping regulations in Brazil.
An estimated 20% of MercadoLibre’s gross merchandise volume in Brazil, according to the analysts, falls between R$19 and R$79. This range excludes supermarket and cross-border transactions and is linked to slower shipping options like MELI Delivery Day.
However, BofA Securities states that a 30% increase in shipment density might balance the cost of the adjustments. Additionally, the firm points at how a single percentage point improvement in advertising penetration or greater earnings power in Argentina could justify the investment.
MercadoLibre, Inc. (NASDAQ:MELI), based in Buenos Aires, Argentina, is a prominent Latin American e-commerce technology company. Established in 1999, the main platforms of the company, MercadoLibre.com and MercadoPago.com, provide a variety of solutions for individuals and businesses engaged in online buying, selling, advertising, and payment operations.
3. Coherent Corp. (NYSE:COHR)
Duquesne Capital’s Stake Value: $144.3 million
Analyst Upside as of June 15: 33.32%
Number of Hedge Fund Holders: 61
Coherent Corp. (NYSE:COHR) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. On June 12, JPMorgan maintained its Overweight rating on Coherent Corp. (NYSE:COHR) but increased its price target from $86 to $100. The upsurge is a result of JPMorgan’s growing confidence in the company’s ability to meet its investor day goals.
The firm modified its projections to take into consideration Coherent’s anticipated trajectory of growth and profitability. In fiscal 2026 and 2027, JPMorgan now projects a 10% increase in revenue, with gross margins of roughly 39% in fiscal year 2026 and 40% in fiscal year 2027. The projected results translate into earnings per share forecasts of $4.50 in FY26 and $5.70 in FY27, which puts JPMorgan’s FY27 estimates 4% higher than the consensus.
Despite finding “multiple levers of upside” to these assumptions, the firm stated that it is making the cautious assumption that Coherent Corp. (NYSE:COHR) would meet its three to four-year targets in four years as opposed to three.
Coherent Corp. (NYSE:COHR) designs and manufactures optoelectronic components, networking solutions, engineered materials, and laser systems for the industrial, communications, electronics, and instrumentation markets.
2. Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Duquesne Capital’s Stake Value: $228.7 million
Analyst Upside as of June 15: 43.82%
Number of Hedge Fund Holders: 64
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. Goldman Sachs analysts began coverage of Teva Pharmaceutical Industries Limited (NYSE:TEVA) with a Buy rating and a price target of $24, on June 6. The analysts’ optimistic view was driven in part by a strengthening core business and growth possibilities in the branded segment.
According to the analysts, Teva’s branded segment, which includes medications like Austedo, Uzedy, Ajovy, and LAI olanzapine, has significant growth potential. They estimate that these assets will generate substantial growth in fiscal year 2027, around 10% higher than the mainstream projections. This optimism stems from recent script data and commercial investments, including direct-to-consumer marketing.
On the other hand, Goldman Sachs analysts see modest growth in the generics sector over the upcoming years. Although Teva’s growing portfolio of biosimilars—five more are anticipated to be introduced in the United States between fiscal years 2025 and 2027—offers potential, the gRevlimid settlement’s expiration in 2026 may offset this growth.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a multinational pharmaceutical company based in Israel. Although generic medications are Teva’s primary area of expertise, the company also has branded drug assets.
1. Natera, Inc. (NASDAQ:NTRA)
Duquesne Capital’s Stake Value: $481.1 million
Analyst Upside as of June 15: 24.83%
Number of Hedge Fund Holders: 67
Natera Inc. (NASDAQ:NTRA) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. Leerink Partners analysts reiterated their Outperform rating on Natera Inc. (NASDAQ:NTRA) on June 4. Given recent adjustments to Medicare’s reimbursement of Natera’s WGS Signatera assay, the analysts maintained their price target for the company at $220.
Natera Inc. (NASDAQ:NTRA) recently revealed that MolDX had approved Medicare coverage for its WGS Signatera assay. The update followed the findings of a bridging study that showed similar performance between the WGS Signatera and the previously released WES Signatera. The WGS Signatera assay has been expanded to encompass a number of ailments, including colorectal cancer, breast cancer, bladder cancer, and pan-cancer immunotherapy monitoring.
Analysts expect that WES Signatera will continue to dominate Signatera volumes in the near term, despite the recent coverage. That said, now that it is eligible for reimbursement, the WGS Signatera assay may see a modest rise in usage.
One of the top providers of cell-free DNA and genetic testing, Natera Inc. (NASDAQ:NTRA) focuses primarily on women’s health, cancer, and organ health.
While we acknowledge the potential of NTRA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NTRA and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None.
